Vitamin C
Vitamin C (ascorbic acid) is an essential water-soluble vitamin that functions as a potent antioxidant, a cofactor for collagen-synthesizing prolyl and lysyl hydroxylases, and a mandatory cofactor for the TET family of DNA demethylases that regulate epigenetic methylation patterns; deficiency produces the connective tissue disorder scurvy, and adequate intake is essential for vascular integrity, immune function, iron absorption, and the maintenance of the epigenetic landscape through TET enzyme activity.
Key Takeaways
- •Vitamin C is the essential cofactor for collagen prolyl-4-hydroxylase and lysyl hydroxylase, which catalyze the post-translational hydroxylation of proline and lysine residues required for collagen triple-helix formation and crosslinking; without adequate vitamin C, collagen synthesis fails and existing collagen denatures, producing the systemic connective tissue breakdown of scurvy.
- •Vitamin C is a required cofactor for the TET family of 5-methylcytosine (5mC) dioxygenases, which oxidize 5mC to 5-hydroxymethylcytosine (5hmC) and subsequent demethylation intermediates; this positions vitamin C as a direct regulator of the epigenetic methylation landscape, with deficiency reducing 5hmC levels and impairing the DNA demethylation that maintains epigenetic plasticity.
- •High-dose intravenous vitamin C is in clinical trials for IDH1/IDH2-mutant cancers because 2-hydroxyglutarate (2-HG), the oncometabolite produced by these mutations, competitively inhibits TET enzymes, and pharmacological ascorbate concentrations may overcome this inhibition and restore epigenetic regulation in mutant cells.
- •Vitamin C significantly enhances non-heme iron absorption from the gut by reducing ferric iron (Fe3+) to the absorbable ferrous form (Fe2+) and forming soluble iron-ascorbate complexes; this is beneficial for iron deficiency but can be dangerous in hereditary hemochromatosis (HFE variants) and other iron overload conditions when taken with iron-containing meals.
- •Vitamin C protects the eNOS cofactor tetrahydrobiopterin (BH4) from oxidation, maintaining eNOS in the coupled state that produces vasodilatory nitric oxide rather than the uncoupled state that produces superoxide; this explains the consistent observation that plasma vitamin C levels correlate with endothelial function and arterial stiffness in clinical studies.
- •In Werner syndrome (WRN helicase deficiency), vitamin C supplementation has been shown to alleviate nuclear blebbing and improve cell proliferation in progerin-expressing cell models, suggesting a role in supporting the structural integrity of the nuclear lamina and the genomic maintenance pathways that are compromised by WRN dysfunction.
- •The relationship between high-dose vitamin C and cardiovascular risk in the context of elevated Lp(a) is an active area of investigation; Lp(a) accumulates at sites of vascular injury and its interactions with the extracellular matrix may be modulated by the collagen integrity and vascular health effects of vitamin C.
Basic Information
- Name
- Vitamin C
- Also Known As
- ascorbic acidascorbateL-ascorbic acidascorbyl palmitate (fat-soluble form)sodium ascorbatecalcium ascorbateliposomal vitamin C
- Category
- Essential vitamin / antioxidant / enzyme cofactor
- Bioavailability
- Oral bioavailability is high at low to moderate doses (approximately 80 to 90 percent at doses below 200 mg per day) but decreases steeply at higher doses due to saturable intestinal transporter capacity (SVCT1 and SVCT2); at 1,250 mg per dose, only approximately 46 percent is absorbed. Unabsorbed vitamin C is osmotically active in the colon and causes dose-dependent diarrhea at high doses (the bowel tolerance limit). Liposomal vitamin C formulations claim improved bioavailability at higher doses, though the evidence is mixed. Plasma vitamin C is tightly regulated between approximately 50 and 80 micromolar in vitamin C-replete individuals regardless of dose beyond 200 mg per day; intravenous vitamin C bypasses this ceiling and achieves millimolar plasma concentrations.
- Half-Life
- Plasma half-life is approximately 10 days when measured across physiological plasma concentrations, but functional tissue turnover is faster. Adrenal glands and brain contain the highest vitamin C concentrations (10 to 50-fold above plasma). Renal clearance of vitamin C increases when plasma concentration exceeds the renal threshold (approximately 70 micromolar), limiting accumulation and requiring continued dietary intake to maintain tissue stores. The body pool is approximately 900 to 1,500 mg in vitamin C-replete adults.
Primary Mechanisms
Prolyl-4-hydroxylase and lysyl hydroxylase cofactor enabling collagen triple-helix stabilization
TET enzyme (5mC dioxygenase) cofactor supporting epigenetic DNA demethylation
Direct antioxidant: electron donation to neutralize hydroxyl radicals, superoxide, and reactive nitrogen species
Vitamin E recycling: reduction of tocopheryl radical back to tocopherol at the membrane-aqueous interface
Iron reduction: ferric to ferrous conversion enhancing non-heme dietary iron absorption
BH4 protection maintaining eNOS coupling and endothelial nitric oxide production
Cytochrome c recycling: regeneration of reduced cytochrome c for mitochondrial Complex IV electron transfer
Quick Safety Summary
Dietary reference intake: 75 to 90 mg per day; tolerable upper intake level: 2,000 mg per day. Supplemental doses of 250 to 1,000 mg per day are widely used and well-tolerated. Intravenous doses of 1 to 100 g per day are used in clinical trials for specific indications. The primary dose-limiting side effect is osmotic diarrhea (bowel tolerance), which varies individually from approximately 2 to 20 g per day.
Hereditary hemochromatosis (HFE variants): vitamin C dramatically increases non-heme iron absorption and should not be taken with iron-rich meals or iron supplements by individuals with iron overload conditions, Renal failure and oxalate kidney stones: vitamin C is metabolized to oxalate; high-dose supplementation increases urinary oxalate excretion and can precipitate calcium oxalate kidney stones in susceptible individuals and in those with renal impairment, G6PD deficiency: intravenous high-dose vitamin C can induce hemolytic anemia in G6PD-deficient individuals; oral supplementation at standard doses is generally safe but high doses should be avoided without testing
Overview
Vitamin C (ascorbic acid) is a six-carbon lactone that humans, unlike most other mammals, cannot synthesize endogenously due to the loss of the final enzymatic step (gulonolactone oxidase, GULO) approximately 63 million years ago in the primate lineage. This evolutionary loss makes dietary vitamin C an absolute requirement for human health. The compound serves as an electron donor in a remarkable range of enzymatic reactions: it is the cofactor for at least eight mammalian enzymes including the collagen-synthesizing prolyl and lysyl hydroxylases, the carnitine biosynthesis enzymes, the catecholamine biosynthesis enzyme dopamine beta-hydroxylase, the neuropeptide amidating enzymes, and the TET family of DNA demethylases. This enzymatic versatility, combined with its role as the primary water-soluble antioxidant in human plasma and extracellular fluid, makes vitamin C one of the most biologically multifunctional micronutrients known. The clinical consequences of deficiency span three domains: connective tissue failure (scurvy), metabolic dysfunction (impaired catecholamine and carnitine synthesis), and epigenetic dysregulation (impaired TET-mediated DNA demethylation).
The collagen-stabilizing role of vitamin C is the best understood and clinically most consequential. Collagen triple helices require the hydroxylation of specific proline and lysine residues to achieve their characteristic right-handed supercoil structure and to provide the crosslinking sites that give collagen its tensile strength. This hydroxylation is catalyzed by prolyl-4-hydroxylase (using proline, molecular oxygen, alpha-ketoglutarate, and vitamin C as substrates) and by lysyl hydroxylase, and vitamin C is consumed rather than merely being a catalytic cofactor, regenerating the active ferrous iron center of these enzymes. Without vitamin C, these hydroxylations fail, the collagen triple helix cannot form, and existing mature collagen gradually denatures. The clinical sequence is the multi-system connective tissue breakdown of scurvy: perifollicular hemorrhages, gingival bleeding and tooth loss, impaired wound healing, and finally death from connective tissue failure. Less severe vitamin C insufficiency produces subclinical impairment of collagen quality in blood vessel walls, skin, and cartilage without the full scurvy syndrome.
The discovery that vitamin C is a required cofactor for the TET family of 5-methylcytosine dioxygenases adds a genomic regulatory dimension to its biochemistry that was not appreciated until the 2010s. TET1, TET2, and TET3 are the enzymes responsible for the active demethylation arm of epigenetic regulation: they catalyze the sequential oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), which are then removed by thymine DNA glycosylase or replication dilution to restore unmethylated cytosine. This pathway is essential for establishing tissue-specific methylation patterns, maintaining pluripotency, and preventing the aberrant methylation silencing of tumor suppressor genes. TET enzymes are alpha-ketoglutarate-dependent dioxygenases that require vitamin C to maintain the iron center in the reduced ferrous state; vitamin C deficiency reduces TET enzyme activity and globally lowers 5hmC levels. This explains why vitamin C status correlates with epigenetic methylation patterns in population studies and why high-dose intravenous vitamin C has entered clinical trials as an epigenetic modifier in IDH1/IDH2-mutant cancers, where the oncometabolite 2-hydroxyglutarate competitively inhibits TET enzymes.
The vascular biology of vitamin C is mechanistically anchored in two complementary pathways. First, vitamin C protects tetrahydrobiopterin (BH4), the essential cofactor for endothelial nitric oxide synthase (eNOS, NOS3), from oxidation by superoxide and peroxynitrite. When BH4 is oxidized to BH2, eNOS becomes uncoupled: rather than producing the vasodilatory and anti-inflammatory gasotransmitter nitric oxide, the uncoupled eNOS generates superoxide instead, worsening the very oxidative stress that triggered the BH4 oxidation. Vitamin C, by scavenging superoxide and recycling oxidized BH4 back to the active form, maintains eNOS coupling and supports the endothelium-dependent vasodilation that is measured clinically as flow-mediated dilatation (FMD). Second, vitamin C is required for the collagen biosynthesis that maintains the structural integrity of blood vessel walls; vitamin C-deficient vessels develop the hemorrhagic fragility that characterizes scurvy at the extreme, and subclinical vitamin C insufficiency correlates with elevated CRP and impaired endothelial function in epidemiological studies.
Gene Interactions
Key Gene Targets
COL1A1
Vitamin C is the critical and consumed cofactor for the prolyl-4-hydroxylase and lysyl hydroxylase enzymes that stabilize the COL1A1-encoded collagen alpha-1(I) chain; vitamin C deficiency prevents the hydroxylation of proline 986 and other key residues, causing collagen triple helices to denature at body temperature and producing the characteristic hemorrhagic and structural failures of scurvy.
DNMT3A
Vitamin C acts as a required cofactor for the TET family of DNA demethylases that oppose DNMT3A-mediated methylation; adequate vitamin C maintains TET enzyme activity and 5hmC levels, supporting the active demethylation that balances DNMT3A methylation activity and preventing the hypermethylation drift at tumor suppressor loci that characterizes aging and early carcinogenesis.
HFE
Vitamin C is essential for health but its iron-absorption-enhancing effects make it potentially dangerous for HFE variant carriers with hereditary hemochromatosis; HFE C282Y or H63D homozygotes who take high-dose vitamin C with iron-containing meals can dramatically accelerate iron loading, and this combination requires avoidance or careful medical monitoring.
IDH1
Vitamin C is the mandatory cofactor for the TET enzymes that are competitively inhibited by 2-hydroxyglutarate (2-HG), the oncometabolite produced by IDH1 gain-of-function mutations; high-dose intravenous vitamin C is in active clinical trials as a strategy to overcome the 2-HG-mediated TET inhibition in IDH1-mutant gliomas and leukemias, restoring the epigenetic regulation of differentiation and tumor suppressor genes.
NOS3
Vitamin C helps protect the essential eNOS cofactor tetrahydrobiopterin (BH4) from oxidation by superoxide and peroxynitrite; when BH4 is oxidized to BH2, eNOS becomes uncoupled and produces superoxide rather than nitric oxide, worsening endothelial dysfunction, and vitamin C breaks this cycle by scavenging the superoxide that causes BH4 oxidation.
Safety & Dosing
Contraindications
Hereditary hemochromatosis (HFE variants): vitamin C dramatically increases non-heme iron absorption and should not be taken with iron-rich meals or iron supplements by individuals with iron overload conditions
Renal failure and oxalate kidney stones: vitamin C is metabolized to oxalate; high-dose supplementation increases urinary oxalate excretion and can precipitate calcium oxalate kidney stones in susceptible individuals and in those with renal impairment
G6PD deficiency: intravenous high-dose vitamin C can induce hemolytic anemia in G6PD-deficient individuals; oral supplementation at standard doses is generally safe but high doses should be avoided without testing
Drug Interactions
Iron supplements: vitamin C dramatically increases iron absorption when taken together; this is beneficial in iron deficiency but should be timed away from meals in hemochromatosis or iron overload contexts
Warfarin: high-dose vitamin C may impair warfarin anticoagulation at doses above 1,000 mg per day in some individuals; INR monitoring is warranted
Statins and niacin: some evidence that high-dose antioxidant combinations including vitamin C and E blunt the HDL-raising effect of niacin-statin therapy; avoid very high doses during niacin therapy
Chemotherapy: the interaction of high-dose vitamin C with cancer chemotherapy is complex and indication-specific; it may be synergistic with some agents (cisplatin) and potentially antagonistic with others; oncology consultation required
Aluminum-containing antacids: vitamin C increases aluminum absorption; avoid concurrent use
Common Side Effects
Osmotic diarrhea and GI discomfort at doses exceeding individual bowel tolerance (typically above 1,000 to 3,000 mg per day in one dose); buffered forms (sodium ascorbate, calcium ascorbate) and splitting doses throughout the day reduce GI side effects
Increased oxalate excretion with doses above 1,000 mg per day; relevant primarily for individuals with a history of calcium oxalate kidney stones
Studied Doses
Dietary reference intake: 75 to 90 mg per day; tolerable upper intake level: 2,000 mg per day. Supplemental doses of 250 to 1,000 mg per day are widely used and well-tolerated. Intravenous doses of 1 to 100 g per day are used in clinical trials for specific indications. The primary dose-limiting side effect is osmotic diarrhea (bowel tolerance), which varies individually from approximately 2 to 20 g per day.
Mechanism of Action
The collagen hydroxylation mechanism requires vitamin C as a consumed stoichiometric cofactor rather than a true catalytic cofactor. Prolyl-4-hydroxylase catalyzes the reaction: proline residue + O2 + alpha-ketoglutarate + Fe2+ yields 4-hydroxyproline + CO2 + succinate. In this reaction, the ferrous iron (Fe2+) center is oxidized to ferric iron (Fe3+) during the catalytic cycle, and ascorbate reduces it back to the ferrous active state, being oxidized to dehydroascorbate in the process. Approximately one molecule of ascorbate is consumed per catalytic cycle, meaning that actively synthesizing collagen fibroblasts have high ascorbate demand and are among the first cells to show functional impairment during vitamin C depletion. The same mechanism operates for lysyl hydroxylase, which hydroxylates lysine residues that then serve as sites for glycosylation and crosslink formation. The quantity and geometry of these hydroxylations determine the mechanical properties of mature collagen fibers, making vitamin C status a direct determinant of connective tissue quality.
The TET enzyme cofactor mechanism is mechanistically analogous: TET1, TET2, and TET3 are alpha-ketoglutarate-dependent dioxygenases that use the same iron-containing active site as prolyl hydroxylase, and they similarly require ascorbate to maintain the iron center in the ferrous catalytic state. The substrate is not amino acid residues in nascent proteins but 5-methylcytosine residues in DNA, which TET enzymes oxidize sequentially to 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine. These oxidized methylcytosine derivatives are then removed by thymine DNA glycosylase through base excision repair, restoring unmodified cytosine and completing the active demethylation cycle. In hematopoietic stem cells, this TET activity is required for normal differentiation and for suppressing leukemic transformation; TET2 is one of the most frequently mutated genes in myeloid malignancies, and its functional loss through either mutation or vitamin C deficiency produces a similar phenotype of impaired differentiation and clonal expansion.
Clinical Evidence
The clinical evidence base for vitamin C spans its classical deficiency syndrome (scurvy), its vascular and endothelial effects, and the emerging epigenetic pharmacology in oncology. Epidemiological studies consistently show inverse correlations between plasma vitamin C levels and cardiovascular disease risk, CRP, and measures of oxidative stress. Randomized trials with supplemental vitamin C have shown modest reductions in systolic blood pressure (approximately 4 mmHg), improvements in flow-mediated dilatation, and reductions in LDL cholesterol in a meta-analysis of 29 trials. In cancer biology, the pivotal Agathocleous et al. 2017 paper established that vitamin C activates TET2 in hematopoietic stem cells and suppresses leukemia development in Tet2-deficient mice, leading to ongoing clinical trials of high-dose intravenous vitamin C in IDH1/IDH2-mutant acute myeloid leukemia. The most convincing human evidence for the TET-epigenetic mechanism comes from studies showing that plasma vitamin C levels directly correlate with 5hmC content in circulating blood cells, and that vitamin C depletion reduces 5hmC globally. The totality of the evidence supports vitamin C as a nutritional factor with genuine pharmacological relevance in specific genetic and disease contexts beyond its classical deficiency prevention role.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Landmark study demonstrating that vitamin C activates TET2 enzyme activity in hematopoietic stem cells, increasing 5hmC levels and suppressing leukemia development in Tet2-deficient mice; the paper established the mechanistic basis for vitamin C as a TET enzyme cofactor and its relevance to epigenetic regulation and leukemia prevention, spawning the clinical investigation of high-dose vitamin C in IDH-mutant hematological malignancies.
Study in 167 healthy adults showing that plasma vitamin C concentration inversely correlates with the rate of spontaneous chromosomal mutation in peripheral blood lymphocytes, providing direct human evidence that physiological vitamin C levels reduce DNA damage rates and supporting the antioxidant-mediated genome protection mechanism.
Mechanistic study demonstrating that vitamin C promotes TET1 and TET2 enzyme activity in human and mouse cells, increasing 5hmC levels in a dose-dependent and enzyme-dependent manner, and that this effect requires the reducing activity of ascorbate rather than simply its antioxidant properties; established the direct biochemical mechanism of vitamin C as a TET enzyme cofactor.
Meta-analysis of 29 randomized controlled trials showing that vitamin C supplementation significantly reduces LDL cholesterol and triglycerides, does not significantly affect HDL, and modestly reduces systolic blood pressure, providing a quantitative summary of the cardiovascular effects of vitamin C supplementation independent of its antioxidant and collagen roles.
Pivotal depletion-repletion pharmacokinetic study in healthy male volunteers establishing the sigmoidal relationship between vitamin C dose and plasma concentration, demonstrating that plasma vitamin C saturates at approximately 80 micromolar with oral doses above 400 mg per day; this study provided the scientific basis for current dietary reference intakes and the understanding that oral supplementation cannot exceed the plasma ceiling achievable by diet alone.